Placebos are used in clinical trials to create a true baseline for comparison, separating the actual biological effects of a drug from the improvements people experience simply because they believe they’re being treated. Without a placebo group, researchers can’t tell whether a new medication genuinely works or whether patients improved on their own, reported feeling better because they expected to, or simply got better because their disease naturally fluctuated over time. The placebo-controlled trial is widely regarded as the gold standard for testing whether new treatments are effective.
What a Placebo Actually Does in a Trial
A placebo is typically a sugar pill or saline injection designed to look identical to the real treatment. Participants who receive it don’t know they’re getting an inactive substance. This setup mimics every part of the treatment experience (taking a pill, visiting the clinic, interacting with doctors) except for the active ingredient being tested.
The placebo group acts as the experiment’s control. When researchers compare outcomes between the drug group and the placebo group, the difference represents the drug’s true effect. If 60% of patients improve on the drug but 40% also improve on the placebo, the drug’s actual contribution is that 20-percentage-point gap, not the full 60%. Without a placebo group, that drug would look far more effective than it really is.
What happens in the placebo group isn’t necessarily a “placebo effect” in the psychological sense. The improvement researchers observe in that group can reflect the natural course of the disease, random symptom fluctuations, regression to the mean (where extreme symptoms naturally drift back toward average), or even other treatments patients are using at the same time. The placebo group captures all of these factors so they can be subtracted from the drug group’s results.
Preventing Bias Through Blinding
Placebos make blinding possible. If everyone knew who was getting the real drug and who wasn’t, both patients and researchers would behave differently, and that behavior would contaminate the results. A patient who knows they’re on the active drug might report improvements more optimistically. A doctor who knows which patients are treated might evaluate them more favorably or monitor them more closely.
In a double-blind trial, neither the patient nor the research team knows who received the drug and who received the placebo. This keeps expectations from influencing how symptoms are reported or how outcomes are measured. Triple blinding goes a step further by also keeping the people who analyze the data in the dark. These layers of blinding are only possible because the placebo looks, tastes, and feels identical to the real treatment.
The Placebo Effect Is Real Biology
Placebos aren’t truly inert once a person takes them. The belief that you’re receiving treatment triggers measurable changes in the brain. Pain relief from a placebo, for example, involves the release of the body’s natural painkillers (endorphins), along with cannabinoids and dopamine. These are the same chemical systems that actual pain medications target.
In people with Parkinson’s disease, placebo treatments have been associated with increased dopamine release in the brain region responsible for movement, leading to real improvements in motor function. The response starts in specific brain areas involved in expectation, emotion, and reward processing. This is why placebos tend to be especially powerful in conditions where symptoms are subjective, like pain, depression, nausea, and fatigue. The brain is generating genuine physiological responses based on the expectation of relief.
This is precisely why clinical trials need a placebo group. If the brain can produce real symptom improvement from belief alone, then any drug tested without a placebo comparison would get credit for improvements the brain generated on its own.
The Nocebo Effect: Side Effects From Nothing
Expectation works in the other direction too. In clinical trials, a substantial proportion of patients in placebo groups report negative side effects, even though they received an inactive substance. This is called the nocebo effect. Interestingly, the side effects reported in the placebo group often match the known side effects of the actual drug being tested.
The explanation lies partly in the informed consent process. Before joining a trial, participants are told about potential side effects of the drug. That information creates negative expectations, and those expectations can produce real symptoms: headaches, nausea, fatigue, dizziness. Brain imaging confirms this is a genuine neurobiological phenomenon, not just people complaining. The nocebo effect is one reason researchers carefully track side effects in the placebo group. It helps distinguish which adverse events are caused by the drug itself and which are caused by the psychology of being in a medical study.
When Placebos Are Not Allowed
Placebos aren’t appropriate in every trial. The Declaration of Helsinki, the international framework for research ethics first adopted in 1964, sets clear boundaries. The core rule: a new drug must be tested against the best existing treatment, not a placebo, when an effective therapy already exists. Giving someone a sugar pill for a treatable condition means deliberately withholding care, which is ethically unacceptable.
Placebos are considered acceptable in two main situations. The first is straightforward: when no proven treatment exists for the condition being studied, there’s nothing to withhold. The second is more nuanced. Placebos can be used even when treatments exist if there are compelling scientific reasons why a placebo comparison is necessary, and if participants won’t face serious or irreversible harm from not receiving the standard treatment. A trial for a new migraine drug might use a placebo group because going untreated for a single migraine episode doesn’t cause lasting damage. A trial for a new cancer drug almost certainly would not.
Placebo vs. Active Control Trials
When a proven treatment exists, trials typically use an “active control” design instead. The new drug is compared against the current standard treatment rather than against a sugar pill. These are called non-inferiority trials because the goal shifts. Instead of proving the new drug beats a placebo, researchers aim to show the new drug works at least as well as the existing one, while possibly offering other advantages like fewer side effects, lower cost, or easier dosing.
Active control trials solve the ethical problem but introduce a scientific tradeoff. They require larger numbers of participants to produce reliable results, and interpreting the data is more complex. If the new drug performs similarly to the existing one, it can be difficult to determine whether both drugs are truly effective or whether neither worked particularly well in that specific trial. Placebo-controlled trials, by contrast, give a cleaner answer about whether a drug works at all. Research has found that trials using standard placebos may overestimate a drug’s true effect by a small but meaningful margin compared to trials using active placebos (placebos designed to mimic the side effects of the real drug, making blinding more convincing).
Why Regulators Still Require Them
Regulatory agencies like the FDA rely heavily on placebo-controlled data when deciding whether to approve a new drug. Phase III trials, the large-scale confirmatory studies that come right before a drug reaches the market, typically require the highest level of evidence. The FDA generally expects a study power of 80% and statistical significance at the p < 0.05 level for comparative trials, meaning results need to be robust enough that there's less than a 5% chance the findings are due to random variation.
Placebo-controlled trials provide the clearest signal of whether a drug actually works, which is why they remain central to the approval process. But regulatory thinking has evolved. Both the FDA and the World Medical Association have recommended restricting placebo use in certain situations, particularly when withholding an effective treatment could harm participants. The trend in clinical research is toward using placebos only when ethically justified and scientifically necessary, while relying on active comparators when established treatments exist.